GUILD Learning and Development has developed an online course titled 'Ryzodeg 70/30 for the management of diabetes: A guide for pharmacists', with the module sponsored by Novo Nordisk.
This course examines the role of Ryzodeg 70/30 (70% long-acting insulin degludec and 30% insulin aspart) in the treatment of diabetes - the first insulin to combine an ultra-long acting insulin with a mealtime insulin in one device.
The course is CPD accredited - contact the Guild on 03 9819 9930 or visit myCPD.org.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Sep 18
